Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan

Autoimmune polyendocrine syndrome (APS) is an autoimmune disease involving at least two endocrine organ. It is classified into type I and type II diseases. Among them, APS type II is more common. It is diagnosed when two of the three following diseases are diagnosed in the same patient, including type 1 diabetes mellitus, autoimmune thyroid disease, and primary adrenal insufficiency. In this study, we will observe the epidemiology, clinical characteristics, and genetic variants of APS II in Taiwan.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Autoimmune Polyendocrine Syndrome Type II Autoimmune Diseases Endocrine System Diseases Immune System Diseases Polyendocrinopathies, Autoimmune

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location status: Recruiting

Location contact

Shyang-Rong Shih, MD. PhD

CONTACT

[email protected]

+886-972653337

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients visited NTUH during 2006-2021, and had at least two of the three diseases: type 1 DM, primary adrenal insufficiency, and autoimmune thyroid disease.

Exclusion criteria

Patients aged less than 20 years old

Treatment and study plan

No intervention

Other

No intervention, only observation

Primary outcomes

Rates of endocrine organs involved

Time frame: 2022/1/1 ~ 2026/12/31

We will observe the rate of each endocrine organ involved, including adrenal gland, thyroid, and pancreas

Study contacts

Contact information is provided by the study sponsor or research team.

Shyang-Rong Shih, MD, PhD

CONTACT

[email protected]

+886-972653337

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2026
Study completion: 2026
First posted: Oct 13, 2022
Registry last updated: Oct 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting